Supernus Pharm (SUPN) Tops Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Supernus Pharm (SUPN) Tops Q1 EPS by 3c

Supernus Announces First Quarter 2014 Results

May 12, 2014 5:37 PM EDT

First quarter product prescriptions, as reported by IMS, totaled 30,208, increasing by 9,098, or 43%, as compared to fourth quarter 2013.   First quarter combined net product revenue for Oxtellar XR and Trokendi XR was $9.0 million.   As of May, the sales force expansion is substantially complete, totaling more than 150 representatives.   Operating loss in the first quarter was $13.4 million, as compared to $11.4 million in the fourth quarter of 2013, reflecting costs associated with the expansion of the sales force.

ROCKVILLE, Md., May 12, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a specialty pharmaceutical company focused on... More